These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32160293)

  • 1. Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis: reply.
    Nevskaya T; Zheng B; Baxter C; Ramey D; Pope JE; Baron M
    Rheumatology (Oxford); 2020 Jul; 59(7):1783-1784. PubMed ID: 32160293
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
    Bosello S; Gremese E; Ferraccioli G
    Rheumatology (Oxford); 2020 Jul; 59(7):1782-1783. PubMed ID: 32160296
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous lesion of progressive systemic sclerosis.
    JAMA; 1961 Apr; 175():1175. PubMed ID: 14447657
    [No Abstract]   [Full Text] [Related]  

  • 4. Distinct gene network in skin lesion of patients with diffuse cutaneous systemic sclerosis.
    Inamo J
    Clin Rheumatol; 2020 Oct; 39(10):3143-3144. PubMed ID: 32588276
    [No Abstract]   [Full Text] [Related]  

  • 5. Pathologic observations concerning the cutaneous lesion of progressive systemic sclerosis: an electron microscopic histochemical and immunohistochemical study.
    FISHER ER; RODNAN GP
    Arthritis Rheum; 1960 Dec; 3():536-45. PubMed ID: 13699954
    [No Abstract]   [Full Text] [Related]  

  • 6. A deeper look at skin scoring in scleroderma - surrogate, outcome, neither or both?
    Seibold JR
    Rheumatology (Oxford); 2020 Feb; 59(2):269-270. PubMed ID: 31586429
    [No Abstract]   [Full Text] [Related]  

  • 7. Revisiting the disease specificity and nomenclature of ficolin-1-positive monocyte-derived dendritic cells in diffuse cutaneous systemic sclerosis: comment on the article by Xue et al.
    Sarfati M; Chapuy L; Mehta H
    Arthritis Rheumatol; 2022 Oct; 74(10):1721-1722. PubMed ID: 35644033
    [No Abstract]   [Full Text] [Related]  

  • 8. Fixation of S 35 in the skin of patients with progressive systemic sclerosis.
    DENKO CW; STOUGHTON RB
    Arthritis Rheum; 1958 Feb; 1(1):77-81. PubMed ID: 13510133
    [No Abstract]   [Full Text] [Related]  

  • 9. Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.
    Hinchcliff M
    Arthritis Rheumatol; 2020 Aug; 72(8):1237-1240. PubMed ID: 32368869
    [No Abstract]   [Full Text] [Related]  

  • 10. A Rare Presentation of Renal Impairment in Diffuse Cutaneous Systemic Sclerosis.
    Solanki KK; Lamont D; White DHN
    J Clin Rheumatol; 2021 Dec; 27(8S):S844. PubMed ID: 32118618
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum levels of mannose-binding lectin in systemic sclerosis: a possible contribution to the initiation of skin sclerosis in the diffuse cutaneous subtype.
    Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    Eur J Dermatol; 2014; 24(1):123-5. PubMed ID: 24566202
    [No Abstract]   [Full Text] [Related]  

  • 12. The nature of joint involvement in progressive systemic sclerosis (diffuse scleroderma).
    RODNAN GP
    Ann Intern Med; 1962 Mar; 56():422-39. PubMed ID: 14493143
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapid skin thickness progression rate is associated with high incidence rate of cardiopulmonary complications in patients with early diffuse cutaneous systemic sclerosis: inception cohort study.
    Wangkaew S; Thongwitokomarn H; Prasertwittayakij N; Euathrongchit J
    Clin Exp Rheumatol; 2020; 38 Suppl 125(3):98-105. PubMed ID: 32865165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Systemic sclerosis--clinical course and treatment possibilities].
    Szymańska E; Maj M; Rudnicka L
    Przegl Lek; 2005; 62(12):1538-41. PubMed ID: 16786791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.
    Shand L; Lunt M; Nihtyanova S; Hoseini M; Silman A; Black CM; Denton CP
    Arthritis Rheum; 2007 Jul; 56(7):2422-31. PubMed ID: 17599771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progressive systemic sclerosis-scleroderma. Experience with 67 cases].
    GONZALEZ A
    Rev Med Chil; 1959 Jul; 87():498-516. PubMed ID: 13850974
    [No Abstract]   [Full Text] [Related]  

  • 17. [Dermatologic and visceral aspects of diffuse and progressive scleroderma (acro-sclerosis) (3 cases)].
    BECHELLI LM; FONSECA LC; PIMENTA WP
    An Bras Derm Sifilogr; 1956 Mar; 31(1):17-45. PubMed ID: 13362913
    [No Abstract]   [Full Text] [Related]  

  • 18. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
    Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
    Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting improvement in diffuse scleroderma: lessons learnt.
    Pope JE
    Ann Rheum Dis; 2016 Oct; 75(10):1741-2. PubMed ID: 27221693
    [No Abstract]   [Full Text] [Related]  

  • 20. Scleroderma and its oral manifestations. Report of three cases of progressive systemic sclerosis (diffuse scleroderma).
    GREEN D
    Oral Surg Oral Med Oral Pathol; 1962 Nov; 15():1312-24. PubMed ID: 13950059
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.